Guangzhou Baiyunshan Pharmaceutical Holdings (00874): Xuhanting granules approved for clinical trial application for children with recurrent respiratory infections.
Baiyunshan (00874) announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. (hereinafter referred to as "Qixing Pharmaceutical"), recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration regarding the new indication for sweating-stopping granules.
Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Qixing Medicine Co., Ltd. (hereinafter referred to as "Qixing Medicine") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the addition of new indications for Xuhan Ting Granules.
Xuhan Ting Granules have the efficacy of nourishing qi and yin, consolidating the surface and stopping sweating. It is used for spontaneous sweating, night sweats, and pediatric night sweats due to qi and yin deficiency. This product is a traditional Chinese medicine compound formulation already on the market, and the current application is to add a clinical trial application for recurrent respiratory infections in children.
Related Articles
Shanghai Laimu Electronics (603633.SH) actual controller Fang Peijiao plans to reduce their stake by no more than 3%.
NET263 Ltd. (002467.SZ) major shareholder Lee Xiaolong plans to reduce his shareholding by no more than 2%.
YIDU TECH (02158) spent approximately 11.2844 million Hong Kong dollars to repurchase 1.9088 million shares on March 16th.
Shanghai Laimu Electronics (603633.SH) actual controller Fang Peijiao plans to reduce their stake by no more than 3%.
NET263 Ltd. (002467.SZ) major shareholder Lee Xiaolong plans to reduce his shareholding by no more than 2%.
YIDU TECH (02158) spent approximately 11.2844 million Hong Kong dollars to repurchase 1.9088 million shares on March 16th.
